KK
IBRX icon

KLP Kapitalforvaltning’s ImmunityBio IBRX Stock Holding History

KLP Kapitalforvaltning’s Portfolio IBRX Stock Details IBRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$714K Buy
81,500
+5,600
+7% +$42.4K ﹤0.01% 1321
2026
Q1 		$582K Buy
75,900
+5,300
+8% +$36.3K ﹤0.01% 1357
2025
Q4 		$140K Buy
70,600
+26,900
+62% +$60.9K ﹤0.01% 1969
2025
Q3 		$108K Hold
43,700
– – ﹤0.01% 2049
2025
Q2 		$115K Sell
43,700
-30,700
-41% -$82.5K ﹤0.01% 1998
2025
Q1 		$224K Buy
74,400
+52,300
+237% +$159K ﹤0.01% 1700
2024
Q4 		$56.6K Buy
+22,100
New +$92.1K ﹤0.01% 2224

Other funds holding IBRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

KLP Kapitalforvaltning's IBRX Position: Q2 2026 in Review

KLP Kapitalforvaltning increased its ImmunityBio (IBRX) stake by 7.4% in Q2 2026, buying an estimated $42.4K and bringing the position to 81,500 shares worth $714K. The position accounts for ﹤0.01% of the portfolio, ranked #1321.

KLP Kapitalforvaltning first reported a position in IBRX in Q4 2024 and has held it in 7 quarters since. 405 funds tracked by Wall St. Rank hold IBRX as of Q2 2026.

  • KLP Kapitalforvaltning held 81,500 shares of ImmunityBio worth $714K as of Q2 2026.
  • KLP Kapitalforvaltning bought 5,600 ImmunityBio shares in Q2 2026, an estimated $42.4K.
  • ImmunityBio made up ﹤0.01% of KLP Kapitalforvaltning's portfolio in Q2 2026, its #1321 holding.
  • KLP Kapitalforvaltning first reported a position in ImmunityBio in Q4 2024 and has held it in 7 quarters since.
  • 405 funds tracked by Wall St. Rank held ImmunityBio as of Q2 2026.

Based on KLP Kapitalforvaltning's 13F filing for Q2 2026, filed 12 Aug 2026.